IN2015KN00262A - - Google Patents

Info

Publication number
IN2015KN00262A
IN2015KN00262A IN262KON2015A IN2015KN00262A IN 2015KN00262 A IN2015KN00262 A IN 2015KN00262A IN 262KON2015 A IN262KON2015 A IN 262KON2015A IN 2015KN00262 A IN2015KN00262 A IN 2015KN00262A
Authority
IN
India
Prior art keywords
forms
isoquinoline
phenoxy
carbonyl
hydroxy
Prior art date
Application number
Other languages
English (en)
Inventor
Claudia Witschi
Jung Min Park
Michael D Thompson
Michael John Martinelli
David A Yeowell
Michael P Arend
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48857025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015KN00262(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of IN2015KN00262A publication Critical patent/IN2015KN00262A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
IN262KON2015 2012-07-16 2013-07-15 IN2015KN00262A (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261672191P 2012-07-16 2012-07-16
US201361768297P 2013-02-22 2013-02-22
US201361832566P 2013-06-07 2013-06-07
PCT/US2013/050539 WO2014014835A2 (en) 2012-07-16 2013-07-15 Crystalline forms of a prolyl hydroxylase inhibitor

Publications (1)

Publication Number Publication Date
IN2015KN00262A true IN2015KN00262A (da) 2015-06-12

Family

ID=48857025

Family Applications (1)

Application Number Title Priority Date Filing Date
IN262KON2015 IN2015KN00262A (da) 2012-07-16 2013-07-15

Country Status (27)

Country Link
US (5) US9115085B2 (da)
EP (3) EP4029854A1 (da)
JP (2) JP6491093B2 (da)
KR (4) KR102318720B1 (da)
CN (9) CN104684897A (da)
AU (1) AU2013290438C1 (da)
BR (1) BR112015001101A2 (da)
CA (1) CA2879242C (da)
CY (2) CY1120805T1 (da)
DK (2) DK2872488T3 (da)
ES (2) ES2905898T3 (da)
FR (1) FR22C1030I2 (da)
HK (1) HK1243409A1 (da)
HR (2) HRP20220182T1 (da)
HU (2) HUE057925T2 (da)
IL (1) IL236626B (da)
IN (1) IN2015KN00262A (da)
LT (3) LT3470397T (da)
MX (1) MX355428B (da)
MY (1) MY182428A (da)
NZ (1) NZ704662A (da)
PL (2) PL3470397T3 (da)
PT (2) PT3470397T (da)
RS (2) RS57795B1 (da)
SG (3) SG10202111314YA (da)
SI (2) SI3470397T1 (da)
WO (1) WO2014014835A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1644336E (pt) 2003-06-06 2011-04-21 Fibrogen Inc Compostos de heteroarilo que contêm azoto e sua utilização no aumento da eritropoetina endógena
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
MY171483A (en) 2012-07-16 2019-10-15 Fibrogen Inc Process for making isoquinoline compounds
ES2905898T3 (es) 2012-07-16 2022-04-12 Fibrogen Inc Formas cristalinas de un inhibidor de prolil hidroxilasa
US8883823B2 (en) * 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
KR102291860B1 (ko) 2013-06-06 2021-08-20 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
CN103694172A (zh) * 2013-12-26 2014-04-02 辽宁亿灵科创生物医药科技有限公司 含氮杂芳基化合物的衍生物
WO2016045125A1 (en) 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CN104892509B (zh) * 2015-06-04 2018-03-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106916105A (zh) * 2015-12-28 2017-07-04 徐州万邦金桥制药有限公司 一种纯化可博美的方法
US11510917B2 (en) 2016-02-19 2022-11-29 Cornell University HIF-stabilization and prevention of hyperoxia-induced neonatal lung disease
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CN108017583B (zh) * 2016-11-01 2021-04-06 徐州万邦金桥制药有限公司 一种可博美的制备方法
CN107382986B (zh) * 2017-08-02 2022-09-20 江苏艾立康医药科技有限公司 4-羟基-1-甲基异喹啉衍生物及其在增加内源性促红细胞生成素中的用途
CN111511371A (zh) * 2017-08-11 2020-08-07 雷迪博士实验室有限公司 罗沙司他的多晶型物和共晶
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
PL3679017T3 (pl) * 2017-09-04 2022-01-17 Sandoz Ag Kokryształ doustnie dostępnego inhibitora hydroksylazy prolilowej hif
CN111978225B (zh) 2018-06-05 2022-03-04 沈阳化工大学 一种三氟乙基硫醚（亚砜）取代苯类化合物及其用途
CN111320583A (zh) * 2018-12-14 2020-06-23 广东东阳光药业有限公司 诺德司他新晶型及其制备方法
CN109369525A (zh) * 2018-12-29 2019-02-22 安礼特（上海）医药科技有限公司 罗沙司它的新晶型及其制备方法
WO2020217190A1 (en) * 2019-04-26 2020-10-29 Dr. Reddy’S Laboratories Limited Process for the purification of roxadustat
CN112679428A (zh) * 2019-10-17 2021-04-20 罗欣药业(上海)有限公司 罗沙司他新晶型及其制备方法
CN114344301B (zh) * 2019-10-22 2023-06-23 苏州科睿思制药有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型
CN110721185B (zh) * 2019-11-13 2022-04-12 南京市儿童医院 罗沙司他用于心肌保护的用途
CN112961107B (zh) * 2019-12-13 2024-06-25 罗欣药业(上海)有限公司 罗沙司他的晶型及其制备方法
EP4121009A4 (en) * 2020-03-17 2024-04-17 Zydus Lifesciences Limited FORMULATION COMPRISING HIF PROLYL HYDROXYLASE INHIBITORS
CN111205224B (zh) * 2020-04-22 2020-08-25 南京佰麦生物技术有限公司 一种罗沙司他水合物的晶型及其制备方法和应用
CN113754569B (zh) * 2020-06-04 2024-07-02 四川国为制药有限公司 一种中间体化合物及其制备方法和用途
CN111533691A (zh) * 2020-06-08 2020-08-14 重庆三圣实业股份有限公司 一种罗沙司他的制备方法
CN114057643B (zh) * 2020-08-04 2023-02-28 成都苑东生物制药股份有限公司 一种罗沙司他共晶及其制备方法
CN112500344B (zh) * 2020-11-18 2022-07-01 江苏豪森药业集团有限公司 罗沙司他晶型及其制备方法
CN112194624A (zh) * 2020-11-18 2021-01-08 江苏豪森药业集团有限公司 一种异喹啉类化合物的晶型及其制备方法
CN115724796A (zh) * 2021-08-26 2023-03-03 成都苑东生物制药股份有限公司 一种罗沙司他新晶型及其制备方法
CN113956200A (zh) * 2021-12-16 2022-01-21 南京威凯尔生物医药科技有限公司 一种粒径控制的罗沙司他原料药的结晶工艺

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
DE59401924D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
DE69736812T2 (de) 1996-11-27 2007-08-09 Bristol-Myers Squibb Pharma Co. Neue integrin rezeptor antagonisten
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1315220B1 (it) * 1999-12-13 2003-02-03 Ipm Ind Plastica Monregalese Telone di foglia pluristrato di materia plastica per pacciamature e/ocome barriera di contenimento di sostanze di trattamento in
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
AU2002312371A1 (en) 2001-06-13 2002-12-23 Roland W. Burli Aryl-benzimidazole compounds having antiinfective activity
EP1401817A4 (en) 2001-06-13 2005-11-02 Genesoft Pharmaceuticals Inc ISOQUINOLINE COMPOUNDS WITH ANTI-INFECTIOUS ACTIVITY
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
CN100522946C (zh) 2001-12-06 2009-08-05 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
PL220457B1 (pl) 2002-12-16 2015-10-30 Kissei Pharmaceutical Kapsułka do leczenia dysurii
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
PT1644336E (pt) 2003-06-06 2011-04-21 Fibrogen Inc Compostos de heteroarilo que contêm azoto e sua utilização no aumento da eritropoetina endógena
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
EP1646611A1 (en) 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
WO2005011696A1 (en) 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
AU2004263508A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
CA2559630C (en) 2004-03-16 2012-04-17 Asahi Kasei Pharma Corporation Fasudil-containing preparation and method of improving stability thereof
CA2567619A1 (en) 2004-05-28 2005-12-15 Fibrogen, Inc. Hif prolyl hydroxylase activity assay
GB2421013B (en) 2004-12-10 2007-07-11 Amcor Flexibles Europe As Packaging with an openable top wall
WO2006094292A2 (en) 2005-03-02 2006-09-08 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
EP1893186A2 (en) 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
WO2006138511A2 (en) * 2005-06-15 2006-12-28 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
JP5161793B2 (ja) 2006-01-27 2013-03-13 フィブロジェン， インコーポレイテッド 低酸素症誘導因子（ｈｉｆ）を安定化するシアノイソキノリン化合物
JP2009528279A (ja) 2006-02-16 2009-08-06 ファイブローゲン、インコーポレーテッド 脳卒中を治療するための化合物および方法
CN103497184A (zh) 2006-04-04 2014-01-08 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
WO2007141743A2 (en) 2006-06-06 2007-12-13 Ranbaxy Laboratories Limited A tablet dosage form comprising cetirizine and pseudoephedrine
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
JP5683058B2 (ja) 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
TW200924768A (en) 2007-10-12 2009-06-16 Astrazeneca Ab Composition
EP2227475B1 (en) 2007-12-03 2014-02-19 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
WO2010022240A1 (en) 2008-08-20 2010-02-25 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
JP5479949B2 (ja) 2009-04-08 2014-04-23 株式会社東芝 測定装置、測定方法、及び二酸化炭素回収システム
JP2010248106A (ja) 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
US8339523B2 (en) 2010-05-18 2012-12-25 Kabushiki Kaisha Toshiba Television apparatus and electronic apparatus
CN101880914B (zh) 2010-05-25 2012-09-12 中国科学院微电子研究所 利用等离子体浸没离子注入制备黑硅的方法
US20140171465A1 (en) 2011-01-13 2014-06-19 Fibrogen, Inc. Methods For Increasing Reticulocyte Hemoglobin Content
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
KR102029951B1 (ko) 2011-07-22 2019-11-08 베이징 베타 파머수티컬 컴퍼니 리미티드 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도
WO2013070908A1 (en) 2011-11-09 2013-05-16 Fibrogen, Inc. Therapeutic method
CN104470899B (zh) 2012-03-09 2017-12-26 菲布罗根有限公司 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
MY171483A (en) 2012-07-16 2019-10-15 Fibrogen Inc Process for making isoquinoline compounds
ES2905898T3 (es) * 2012-07-16 2022-04-12 Fibrogen Inc Formas cristalinas de un inhibidor de prolil hidroxilasa
RU2666144C2 (ru) 2013-01-24 2018-09-06 Фиброген, Инк. Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты
KR102291860B1 (ko) 2013-06-06 2021-08-20 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형

Also Published As

Publication number Publication date
MX2015000504A (es) 2015-07-17
LTPA2022510I1 (da) 2022-07-25
EP2872488A2 (en) 2015-05-20
KR102318720B1 (ko) 2021-10-28
AU2013290438C1 (en) 2019-01-03
DK3470397T3 (da) 2022-03-14
JP2015522616A (ja) 2015-08-06
EP2872488B1 (en) 2018-08-22
JP6491093B2 (ja) 2019-03-27
LT2872488T (lt) 2018-10-25
HUE057925T2 (hu) 2022-06-28
CA2879242C (en) 2023-05-09
SG11201500236SA (en) 2015-02-27
NZ704662A (en) 2017-07-28
US20150322015A1 (en) 2015-11-12
CN115093370A (zh) 2022-09-23
WO2014014835A2 (en) 2014-01-23
CN107540607A (zh) 2018-01-05
HK1243409A1 (zh) 2018-07-13
ES2905898T3 (es) 2022-04-12
CN107382860A (zh) 2017-11-24
DK2872488T3 (da) 2018-10-29
CN107382859A (zh) 2017-11-24
PL2872488T3 (pl) 2019-01-31
EP4029854A1 (en) 2022-07-20
US10118897B2 (en) 2018-11-06
KR20150058154A (ko) 2015-05-28
CN107382859B (zh) 2018-09-14
CN104684897A (zh) 2015-06-03
US20170190667A1 (en) 2017-07-06
KR20200102556A (ko) 2020-08-31
PT2872488T (pt) 2018-11-22
US20140303202A9 (en) 2014-10-09
EP3470397A1 (en) 2019-04-17
HRP20181751T1 (hr) 2018-12-28
FR22C1030I2 (fr) 2024-08-02
RS63122B1 (sr) 2022-05-31
CY1125155T1 (el) 2023-01-05
HUE041458T2 (hu) 2019-05-28
HRP20220182T1 (hr) 2022-04-29
CY1120805T1 (el) 2019-12-11
BR112015001101A2 (pt) 2017-06-27
WO2014014835A3 (en) 2014-08-21
RS57795B1 (sr) 2018-12-31
PT3470397T (pt) 2022-02-18
US20200115344A1 (en) 2020-04-16
CN103539735B (zh) 2017-08-04
AU2013290438B2 (en) 2017-09-14
KR20210130849A (ko) 2021-11-01
SI3470397T1 (sl) 2022-07-29
US20140024676A1 (en) 2014-01-23
AU2013290438B9 (en) 2018-07-19
CN109369524A (zh) 2019-02-22
CN107501177B (zh) 2018-12-07
US9115085B2 (en) 2015-08-25
AU2013290438A1 (en) 2015-02-19
US20190276408A1 (en) 2019-09-12
PL3470397T3 (pl) 2022-06-20
CN114409596A (zh) 2022-04-29
SG10202111314YA (en) 2021-12-30
WO2014014835A8 (en) 2014-11-20
CA2879242A1 (en) 2014-01-23
LT3470397T (lt) 2022-02-25
SI2872488T1 (sl) 2018-11-30
US9617218B2 (en) 2017-04-11
KR20220164068A (ko) 2022-12-12
EP3470397B1 (en) 2021-12-29
KR102149380B1 (ko) 2020-08-28
SG10201700873UA (en) 2017-04-27
JP2018009034A (ja) 2018-01-18
MX355428B (es) 2018-04-18
ES2689430T3 (es) 2018-11-14
CN103539735A (zh) 2014-01-29
IL236626A0 (en) 2015-02-26
MY182428A (en) 2021-01-25
IL236626B (en) 2020-03-31
CN107501177A (zh) 2017-12-22
FR22C1030I1 (fr) 2022-09-09

Similar Documents

Publication Publication Date Title
IN2015KN00262A (da)
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2015000962A (es) COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(ß-D-GLU COPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS.
HUE049168T2 (hu) L-aminosav elõállítására képes mikroorganizmus és eljárás L-aminosav elõállítására annak alkalmazásával
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MX2015009617A (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
MX362858B (es) Proceso para la preparacion de pemetrexed y sal de lisina del mismo.
MX347541B (es) Analogos de acido sialico.
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
IN2015DN00085A (da)
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
IN2014KN02722A (da)
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
MX2015005510A (es) Forma salina solida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
WO2014083575A3 (en) Improved process for the preparation of boceprevir intermediate
IN2013CH04314A (da)
WO2014076616A3 (en) Formulations of 5-azacytidine
WO2014122671A3 (en) Solid oral compositions of saxagliptin
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
WO2013046233A3 (en) Process for the preparation of octreotide acetate
IN2015DN02660A (da)
IN2014DN10683A (da)
WO2013064326A3 (de) Arjunolsäure zur erhöhung der sebumproduktion
IN2013MU02771A (da)